Precision cancer medicine using high-throughput sequencing for advanced cancer
Precision Cancer Medicine for Advanced Cancer Through High-throughput Sequencing
This study is collecting tumor samples from patients with advanced cancer to see if their genetic information can help find better treatment options in the future.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Ohio State University Comprehensive Cancer Center Academic / other |
| Locations | 1 site (Columbus, Ohio) |
| Trial ID | NCT02090530 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on collecting tumor specimens from patients with advanced cancer for genomic testing. It utilizes CLIA-certified tests to ensure accurate and precise results, which can help determine eligibility for other clinical trials. The study does not involve any treatment; instead, it aims to gather valuable data through biospecimen collection for future research. Patients may undergo tissue biopsies or provide leftover specimens from standard care procedures for molecular evaluation.
Who should consider this trial
Good fit: Ideal candidates include patients with a confirmed diagnosis of any malignancy who can provide suitable tumor specimens for testing.
Not a fit: Patients who are not diagnosed with cancer or do not have suitable tumor tissue for biopsy may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance personalized treatment options for cancer patients by identifying specific genomic alterations.
How similar studies have performed: Other studies utilizing high-throughput sequencing for cancer genomics have shown promising results, indicating potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. A histologically or cytologically confirmed diagnosis of cancer 2. Patients with any malignancy. 3. Patients must have tumor suitable for research tumor biopsy (as assessed by trained specialists in interventional radiology) and Patients are medically fit to undergo a tissue biopsy or surgical procedure to get tumor tissue OR If Patients do not have a tumor suitable for biopsy but have another tissue available for molecular evaluation. OR Patients are undergoing standard of care surgeries or procedures where fresh specimens will be first used for routine pathologic assessment and only then will leftover tissue be used for research purposes. 4. Procedure-specific signed informed consent prior to initiation of any study-related procedures. 5. Women and minorities are included in this protocol. 6. Patients with multiple malignancies remain eligible. 7. Patients with an inherited cancer syndrome or a medical history suggestive of an inherited cancer syndrome remain eligible. Exclusion Criteria: 1. It is the enrolling study physicians discretion to decide if a patient is not fit enough to undergo tissue biopsy. 2. Patients who are incarcerated are not eligible to participate.
Where this trial is running
Columbus, Ohio
- Ohio State University Wexner Medical Center — Columbus, Ohio, United States (Recruiting)
Study contacts
- Principal investigator: Sameek Roychowdhury, MD, PhD — Ohio State University
- Study coordinator: Ohio State University Comprehensive Cancer Center
- Email: OSUCCCClinicaltrials@osumc.edu
- Phone: 1-800-293-5066
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.